Conclusion: Our findings represent the most comprehensive available evidence base to inform patients, families, clinicians, guideline developers, and policymakers on the choice of ADHD medications across age groups. Taking into account both efficacy and safety, evidence from this meta-analysis supports methylphenidate in children and adolescents, and amphetamines in adults, as preferred first-choice medications for the short-term treatment of ADHD. New research should be funded urgently to assess long-term effects of these drugs.
PubMed 30097390 ↗Methylphenidate
Also known as Ritalin, Concerta
The short answer. Most people who report on Methylphenidate say it did not help (only 39% of 352 positive). It is most often used for focus: 83% of 262 reports say that improved. It is well studied — 383 meta-analyses on PubMed. The most common complaint is anxiety.
From 567 mentions in total — the rest didn't say how it went and aren't counted.
What Methylphenidate does, according to users
Of the people who reported each effect, the share who said it got better.
3 more with fewer than 3 reports
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 383 meta-analyses on PubMed ↗ · 1,123 randomized trials ↗
Conclusion: In addition to being efficacious in reducing ADHD core symptom severity, both stimulant and nonstimulant medications are efficacious in improving QoL in people with ADHD, albeit with lower effect sizes. Future research should explore whether, and to what degree, combining pharmacological and nonpharmacological interventions is likely to further improve QoL in people with ADHD.
PubMed 38823477 ↗Conclusion: Overall, despite a class effect of improving clinical response relative to placebo, there were few differences among the individual ADHD pharmacotherapies, and most studies were at risk of at least one important source of bias. Furthermore, the certainty of the evidence was very low to low for all outcomes, and there was limited reporting of long-term adverse events. As such, the choice between ADHD pharmacotherapies may depend on individual patient considerations, and future studies should assess the long-term effects of individual pharmacotherapies on patient-important outcomes, including qu
PubMed 33085721 ↗Conclusion: On the basis of the results of this literature review, the authors recommend avoiding benzodiazepines and haloperidol for treating agitation and/or aggression in the context of TBI. Atypical antipsychotics (olanzapine in particular) can be considered as practical alternatives for the as-needed management of agitation and/or aggression in lieu of benzodiazepines and haloperidol. Amantadine, β-blockers (propranolol and pindolol), antiepileptics, and methylphenidate can be considered for scheduled treatment of agitation and/or aggression in patients with TBI.
PubMed 33656478 ↗539 human trials on ClinicalTrials.gov test Methylphenidate — 346 completed, 38 recruiting now. See all on ClinicalTrials.gov ↗
- Brain Dopaminergic Signaling in Opioid Use Disorders · Normal Physiology, Opioid Use Disorders · 2025
- Adjunctive Methylphenidate ER in Patients With Schizophrenia to Improve Functional and Cognitive Outcomes · Schizophrenia Schizoaffective · 2024
- Neurocognitive Effects of Extended-Release Methylphenidate in Healthy Adults · Healthy Adult Male and Female Volunteers · 2024
What government agencies say
Official records from US, Canadian and EU regulators, each linked to its source.
Methylphenidate is a Schedule II controlled substance in the US. DEA controlled-substance list ↗
Boxed warning (the FDA's strongest label warning): “ABUSE, MISUSE, AND ADDICTION Methylphenidate hydrochloride extended-release tablets have a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including methylphenidate hydrochloride…”
55 recalls of products named for Methylphenidate. Most recent:
- 2024-07-10 · Class II: Failed dissolution specifications: this product is being recalled due to this batch not meeting dissolution specifications. record ↗
- 2023-08-02 · Class II: Presence of Foreign Substance: Metal embedded in a tablet. record ↗
- 2023-03-29 · Class II: Defective Delivery System: Out of specification for shear. record ↗
Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗
73,102 adverse-event reports mention Methylphenidate. Most often reported:
- Off label use · 7,799
- Drug ineffective · 7,512
- No adverse event · 7,043
- Product quality issue · 5,591
- Fatigue · 3,318
- Headache · 3,169
Reports often involve several drugs and serious illness; a report doesn't prove the drug caused the problem, and these counts can't tell you how often it happens. Source query (openFDA) ↗
LiverTox rates Methylphenidate C — a probable rare cause of liver injury (3–12 published cases). LiverTox entry ↗
NIH has funded 89 research projects with Methylphenidate in the title, $75,383,530 in total (1985–2026). NIH RePORTER ↗
Plain-language guides from the US government: MedlinePlus: Methylphenidate ↗
Dosage people report
Reported side effects
How often each side effect came up across all reports.
What users say
First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.
“I tried both ritalin worked way better in me like way better.”
“I take methylphenidate and it’s changed my life for the way way better.”
“I got diagnosed with ADHD and tried Ritalin and Elvanse and they do help somewhat when I need to learn for an exam but I hate the feeling of being on them.”
“Concerta, Vyvanse (they gave me stimulation and a mood booster but it felt really artificial, left me with more depression when I was not taking it)”
Top discussions (5)
- Just an FYI: be extremely careful with prescription amphetamines…. The road off them is long and painful. ↗
- People who want to start taking SSRIs or other antidepressants must be aware of this!! ↗
- Mystery illness ↗
- Using methylphenidate, citicoline, alpha-GPC, and phosphatidylserine ↗
- Rating every nootropic I've taken ↗
Methylphenidate compared
Other options for focus
Sources
- User reports: 567 mentions in public discussions, quoted with a link to each discussion (e.g. this thread ↗).
- PubMed (US National Library of Medicine, NIH): meta-analyses ↗ · randomized trials ↗
- ClinicalTrials.gov (NIH): registered trials ↗
- FDA drug label (DailyMed) ↗
- FDA adverse-event reports (FAERS) ↗
- FDA recalls ↗
- US DEA ↗
- LiverTox (NIH) ↗
- MedlinePlus (NIH) ↗
- NIH RePORTER ↗
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate